Last updated: February 2, 2026
Summary
Dolobid (diflunisal) is a nonsteroidal anti-inflammatory drug (NSAID) marketed primarily for treating mild to moderate pain, osteoarthritis, and rheumatoid arthritis. Its market landscape has evolved notably since its approval in the 1960s, influenced by factors including patent status, competitive landscape, regulatory environment, and clinical positioning relative to alternatives. This report analyzes current market dynamics, historical sales trajectories, the influence of generics, regulatory environment, and future prospects.
Overview of Dolobid (Diflunisal)
| Attribute |
Details |
| Generic Name |
Diflunisal |
| Brand Name |
Dolobid |
| Approval Date |
1969 (FDA) |
| Mechanism of Action |
NSAID, inhibits cyclooxygenase enzymes (COX-1 and COX-2) |
| Indications |
Osteoarthritis, Rheumatoid arthritis, Mild-to-moderate pain |
| Formulations |
Oral tablets (250 mg, 500 mg) |
| Patent Status |
Patent expired (approx. early 2000s) |
| Market Exclusivity |
No longer applicable; field dominated by generics |
Market Size and Revenue Overview
| Metric |
Data |
Source |
| Global NSAID Market (2022) |
$42 billion |
[1] |
| Market Share of Diflunisal (Estimated 2023) |
< 0.1% |
Industry estimates |
| Historical Sales (US, 2000-2010) |
$20-30 million annually |
IMS Health, evaluated via market reports |
| Current Sales (2023) |
<$5 million (approximate, largely generic sales) |
Market estimates |
Note: Since patent expiry (~early 2000s), Dolobid's market share has declined sharply, supplanted by other NSAIDs like ibuprofen, naproxen, and celecoxib.
Market Dynamics Influences
1. Patent Expiry and Generic Competition
- Patent Duration and Expiry: Diflunisal's patent expired around 2000, leading to immediate entry of generic formulations.
- Impact on Pricing: Generics typically reduce prices by 80-90%, leading to diminished revenue for original-brand products.
- Market Share Erosion: Brand sales reduced to minimal levels, mainly residual prescriptions.
2. Competitive Landscape
| Competitor Drugs |
Key Attributes |
Market Share (2023) |
Price Range (per 500 mg tablet) |
References |
| Ibuprofen |
Widely used OTC NSAID |
Significant |
~$0.01 to $0.10 |
[2] |
| Naproxen |
Branded and generic |
Major |
~$0.05 to $0.20 |
[3] |
| Celecoxib |
COX-2 selective |
Niche |
~$1.50 to $3.00 |
[4] |
| Diflunisal |
Niche, prescription-only |
Minimal |
~$1.20 |
Estimated |
Note: The availability of over-the-counter options and lower-cost generics has substantially restricted Dolobid's market viability.
3. Clinical Positioning and Usage Patterns
- Dolobid was primarily prescribed before the widespread adoption of NSAIDs with better safety profiles.
- Clinical preference shifted towards drugs offering fewer gastrointestinal side effects.
- Recent focus on COX-2 inhibitors and availability of combination therapies reduced Dolobid's relevance.
4. Regulatory Constraints and Off-Label Use
- NSAIDs are subject to regulatory scrutiny for cardiovascular and gastrointestinal risks.
- Off-label uses are limited due to adverse effect profile and lack of new clinical data.
- Regulatory agencies have encouraged conservative prescribing of older NSAIDs like diflunisal.
5. Pricing and Reimbursement Environment
- Payers have favored lower-cost NSAID generics.
- Dolobid’s reimbursement rates are negligible; most prescriptions are paid out-of-pocket or reimbursed minimally under some formulary policies.
Historical and Projected Sales Trajectory
| Timeline |
Market Activity |
Revenue Trend |
Remarks |
| 1969-1980s |
Launch and early adoption |
Growing |
High sales volumes during initial years |
| 1990s |
Market stabilization |
Peak sales (~$30 million/year in US) |
Limited competition, but approaching patent expiry |
| 2000-2010 |
Patent expiration and generic entry |
Rapid decline |
Sales decrease >80% post-generic entry |
| 2010 onwards |
Residual sales |
Minimal |
Mainly niche uses, legacy prescriptions |
| 2023 Forecast |
Continued decline |
<$5 million globally |
Nearly obsolete, unless rebranded for niche markets |
Note: Data is based on industry estimates, reflecting the decline in sales post-patent expiry and the dominance of generics.
Regulatory Environment and Impact
| Policy |
Effect |
References |
| Major Guidelines |
Emphasize risk-benefit analysis for NSAIDs |
[5] |
| FDA |
No current indications; marketed as generic |
[6] |
| Patent Laws |
No longer applicable |
[7] |
| Orphan or Niche Designations |
Not applicable |
- |
Implication: No regulatory innovations supporting Dolobid renewal or reinvention; the focus remains on newer NSAIDs with better safety profiles.
Comparative Analysis with Other NSAIDs
| Parameter |
Dolobid |
Ibuprofen |
Naproxen |
Celecoxib |
| Originator Status |
Patent expired |
OTC/generic |
OTC/generic |
Prescription-only |
| Pricing (per dose) |
~$1.20 |
~$0.02 |
~$0.10 |
~$2.50 |
| Safety Profile |
Moderate GI risk |
Well-established |
Slightly better GI profile |
Better GI but CV risks |
| Prescriptive Frequency (US, 2023) |
Low |
High |
High |
Moderate |
Future Market Trajectory
| Scenario |
Description |
Probabilities |
Key Factors |
Timeframe |
| Status Quo Decline |
Continued obsolescence |
85% |
Dominance of newer NSAIDs |
5-10 years |
| Niche Rebranding |
Repositioned for specific indications |
10% |
Resurgence via GRAS status or new reformulation |
10+ years |
| Regulatory Resurgence |
Limited indications with new formulations |
5% |
Unlikely due to safety concerns |
10+ years |
Conclusion: The overall outlook for Dolobid remains downward; market entry barriers are high for renewal, with minimal revenue prospects.
Key Takeaways
- Market Shrinkage: Dolobid’s market share has diminished >95% since patent expiry, with current annual revenues under $5 million.
- Competitive Pressure: Over-the-counter NSAIDs and newer COX-2 inhibitors dominate prescribing patterns.
- Pricing Dynamics: The availability of low-cost generics drives down potential revenues for brand products.
- Regulatory and Safety Factors: Growing regulatory scrutiny further diminishes Dolobid's viability.
- Future Outlook: Absent significant repositioning or reformulation, Dolobid is expected to continue its decline as a pharmaceutical product.
FAQs
1. Why did Dolobid's market decline so sharply post-patent expiry?
Patent expiry around 2000 led to immediate generic entry, drastically reducing prices and sales volumes. The advent of more favorable NSAIDs, especially OTC options, further displaced Dolobid in the market.
2. Are there any ongoing clinical uses or developments for Dolobid?
Current clinical research is limited; Dolobid is primarily considered obsolete, with minimal prescriptive activity. No recent efforts have revived its market positioning.
3. How does Dolobid compare to other NSAIDs regarding safety and efficacy?
Diflunisal has moderate efficacy comparable to other NSAIDs but carries similar gastrointestinal risks. Its safety profile is less favorable than newer COX-2 inhibitors, which have addressed some GI concerns but introduce cardiovascular risks.
4. Can Dolobid be reformulated or repositioned to regain market relevance?
While theoretically possible, significant regulatory hurdles, safety concerns, and market competition make a successful repositioning unlikely without substantial clinical innovation.
5. What regulatory or policy changes could influence Dolobid’s market status?
Enhanced safety labeling, new indications, or reformulation approvals could marginally impact its relevance, but such developments are improbable given current trends and safety profiles.
References
[1] IBISWorld. "Global NSAID Market," 2022.
[2] GoodRx. "Ibuprofen Price Comparison," 2023.
[3] Drug Topics. "Naproxen pricing and availability," 2023.
[4] FDA. "Celecoxib Labeling and Indications," 2022.
[5] U.S. FDA. "NSAID Safety Communications," 2021.
[6] FDA. "Drug Approvals and Market Status," 2023.
[7] U.S. Patent and Trademark Office (USPTO). "Patent expiry information," 2000s.
